Claims
- 1. A method for determining the risk of a urologic event in a man, comprising measuring the serum PSA of the man.
- 2. The method according to claim 1, wherein the urologic event is selected from BPH-related surgery and acute urinary retention.
- 3. The method according to claim 2, wherein the urologic event is BPH-related surgery.
- 4. The method according to claim 2, wherein the urologic event is acute urinary retention.
- 5. The method according to claim 1, wherein the total serum PSA of the man is measured.
- 6. The method according to claim 1, wherein free serum PSA of the man is measured.
- 7. The method according to claim 1, wherein the percent free serum PSA of the man is measured.
- 8. The method according to claim 1, for determining the risk of a urologic event in a man, comprising measuring the serum PSA of the man, and determining if the value is over 1.3 ng/mL.
- 9. The method according to claim 1, for determining the risk of a urologic event in a man, comprising measuring the serum PSA of the man, and determining if the value is over 3.3 ng/mL.
- 10. A method for reducing the risk of a urologic event in a man at risk for a urologic event according to risk determination method of claim 1, comprising administration of an inhibitor of 5α-reductase to the man.
- 11. A method for reducing the risk of a urologic event in a man at risk for a urologic event according to risk determination method of claim 1, comprising administration of a compound of structural formula I to the subject:
- 12. The method according to claim 11, wherein R is selected from:
(a) unsubstituted C1-10 alkyl, and (b) phenyl unsubstituted or substituted with one or trifluoromethyl substituents.
- 13. The method of claim 11, wherein R is t-butyl.
- 14. The method of reducing the risk of precipitated acute urinary retention according to claim 11, wherein R is 2,5-bis(trifluoromethyl)phenyl.
- 15. The method according to claim 9, comprising administration of finasteride at a dose of 5 mg per day.
- 16. A method for reducing the risk of a urologic event in a man at risk for a urologic event by having a serum PSA level of over 1.3 ng/mL, comprising administration of an inhibitor of 5α-reductase to the man.
- 17. The method according to claim 16, comprising administration of a compound of structural formula I to the subject:
- 18. The according to claim 17, wherein R is selected from:
(a) unsubstituted C1-10 alkyl, and (b) phenyl unsubstituted or substituted with one or two trifluoromethyl substituents.
- 19. The method of claim 17, wherein R is t-butyl.
- 20. The method of reducing the risk of precipitated acute urinary retention according to claim 16, wherein R is 2,5-bis(trifluoromethyl)phenyl.
- 21. The method according to claim 16, comprising administration of finasteride at a dose of 5 mg per day.
- 22. A method for reducing the risk of a urologic event in a man at risk for a urologic event by having a serum PSA level of over 3.3 ng/mL, comprising administration of an inhibitor of 5α-reductase to the man.
- 23. The method according to claim 22, comprising administration of a compound of structural formula I to the subject:
- 24. The method according to claim 22, comprising administration of finasteride at a dose of 5 mg per day.
- 25. A kit for determining the risk of a urologic event in a male subject comprising a test for serum PSA measurement and a means for relating the serum PSA measurement to the risk of a urologic event.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application claims priority of U.S. provisional application Serial No. 60/099,620, filed Sep. 9, 1998.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60099620 |
Sep 1998 |
US |